|
|
|
|
|
|
|
|
|
|
|
 
|
Pancreas Cancer
News and Archives |
|
|
SuperGen Announces Additional
Data from Phase III Study of Orathecin(TM) in Patients With Advanced
Pancreatic Cancer SuperGen Inc. today announced additional data from the company's Phase III clinical study of the investigational drug Orathecin(TM) (rubitecan) capsules as a treatment for refractory or resistant pancreatic cancer. The company had previously announced selected clinical findings from this study that were presented on May 30, 2003, at a satellite symposium prior to the opening of the 39th Annual Meeting of the American Society of Clinical Oncology. The study randomized 409 patients, most of whom had previously failed two or more chemotherapies, to Orathecin or 'best choice'. The primary study end-point was overall survival with secondary end-points of tumor response and time to disease progression. As previously stated, the primary end-point was not met, however both secondary end-points were achieved. The secondary end-points were independent of crossover effect whereas the primary end-point was not. ...full article |
||
|
||
|
For educational
purposes only; not to be relied upon Please read Pancreatica Disclaimer |
||
 Home | In The News | Links | Newswire | Donations FAQ | Clinical Trials Database | Research Resources | About Us |
||
|
|
||
|
www.pancreatica.org |
||